Tarceva® (erlotinib) tablets
Now FDA-approved as maintenance therapy for NSCLC
Tarceva monotherapy is indicated as maintenance treatment in patients with locally advanced or metastatic NSCLC who disease has not progressed after four cycles of platinum-based first-line chemotherapy.
Tarceva is also approved for patients with locally advanced or
metastatic NSCLC whose disease has progressed after one or more courses of chemotherapy. Tarceva is not meant to be used at the same time as certain types of chemotherapy for NSCLC. In pancreatic cancer, Tarceva is approved for the 1st line treatment of locally advanced, unresectable or metastatic pancreatic cancer in combination with gemcitabine (chemotherapy).
See below for important safety information.*
See Tarceva Prescribing Information
Oncology
Because every day is precious for our patients
An important part of our mission is to improve upon the available treatment options for patients suffering from cancer with treatments such as our flagship product, Tarceva. OSI scientists are at the forefront of a paradigm-shifting movement toward molecular targeted, better tolerated and personalized therapies.
Access more information on our oncology programs
Diabetes & Obesity
Novel therapeutic approaches to tackling type 2 diabetes and obesity
We’re all about developing personalized medicines that can improve the lives of patients and have potential drug candidates for type 2 diabetes and obesity, two areas with major unmet medical needs.
Access more information on our diabetes and obesity programs
* Rash and diarrhea were the most common side effects associated with Tarceva in the NSCLC clinical studies. Fatigue, rash, nausea, loss of appetite and diarrhea were the most common side effects associated with Tarceva plus gemcitabine therapy in the pancreatic cancer clinical study.
Now enrolling patients in a Phase III trial studying OSI-906 in patients with adrenocortical carcinoma who have received at least 1 but no more than 2 prior treatments.
Learn more about the study
As we move to our new campus in Ardsley, NY we are looking for people who share our dedication to helping patients, healthcare professionals and the community at large to join our talented and energetic team. We're hiring for a range of positions.
Learn more about the opportunities that await you
OSI’s Oncology research team strives to be a world leader in the development of Molecular Targeted Therapies for the treatment of cancer through exploiting the science underpinning the Epithelial Mesenchymal Transition (EMT).
Learn more